Read full article on CureToday:
- SH-110, a liquid medication for glioma, received FDA orphan drug designation, improving treatment options for patients with swallowing difficulties.
- Orphan drug status offers incentives such as tax credits, user fee waivers, and seven years of market exclusivity upon approval.
